合富（中国）医疗科技股份有限公司 关于 2025 年半年度计提资产减值损失的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次计提资产减值准备情况的概述 合富（中国）医疗科技股份有限公司（以下简称"公司"）根据《企业会计 准则》及公司会计政策等相关规定，基于谨慎性原则，对本公司截至 2025 年 6 月 30 日合并范围内的各项资产进行了减值迹象的识别和测试，并对存在减值迹 象的资产计提相应减值准备，确认资产减值损失及信用减值损失合计人民币 820.86 万元。具体情况如下： 证券代码：603122 证券简称：合富中国 公告编号：临 2025-036 （二）资产减值损失 根据《企业会计准则第1号—存货》及公司相关会计政策，在资产负债表日， 存货按照成本与可变现净值孰低计量，按单个存货项目计算的成本高于其可变现 净值的差额，计提存货跌价准备，计入当期损益。根据减值测试结果，本公司2025 年半年度计提资产减值损失人民币157.03万元，均为存货跌价损失。 三、本次计提减值准备对公司的影响 公司2025年半年度计提信用 ...

证券代码：603122 证券简称：合富中国 公告编号：临 2025-035 合富（中国）医疗科技股份有限公司 关于 2025 年半年度募集资金 存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 （一）募集资金管理情况 为规范公司募集资金管理和使用，保护投资者权益，按照《中华人民共和国 公司法》《中华人民共和国证券法》《上海证券交易所股票上市规则》《上市公 司募集资金监管规则》和《上海证券交易所上市公司自律监管指引第1号——规 范运作》等有关法律、法规和规范性文件的规定，结合公司实际情况，公司已制 定了《募集资金管理制度》，对募集资金实行专户存储制度，对募集资金的存放、 使用、项目实施管理、投资项目的变更及使用情况的监督进行了规定。公司于2022 年2月与保荐机构海通证券股份有限公司（现已更名为国泰海通证券股份有限公 司，以下简称"保荐机构"）、存放募集资金的上海银行虹桥路支行、兴业银行 股份有限公司上海分行营业部、富邦华一银行有限公司上海徐 ...

合富（中国）医疗科技股份有限公司 第三届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 合富（中国）医疗科技股份有限公司（以下简称"公司"）第三届董事会第 二次会议于 2025 年 8 月 25 日上午在上海市虹漕路 456 号光启大楼 20 楼公司董 事会议室/北京市朝阳区东三环北路 19 号嘉盛中心 1810 室以现场与视讯相结合 的方式召开。会议通知于 2025 年 8 月 15 日以电子邮件方式发出。本次会议由董 事长李惇先生主持，应到董事 6 人，实到董事 6 人。部分高级管理人员列席了会 议。会议的召开符合法律法规、《公司法》及《公司章程》的规定，会议决议合 法、有效。 与会董事认真审议了所有议案，经书面投票表决，形成了如下决议： 证券代码：603122 证券简称：合富中国 公告编号：临 2025-034 2、审议并通过了《关于 2025 年半年度募集资金的存放与实际使用情况的 专项报告的议案》。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.c ...

合富（中国）医疗科技股份有限公司2025 年半年度报告 公司代码：603122 公司简称：合富中国 合富（中国）医疗科技股份有限公司 2025 年半年度报告 1 / 152 合富（中国）医疗科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人王琼芝、主管会计工作负责人王琼芝及会计机构负责人（会计主管人员）高恒 正声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 报告期内，本公司未拟定半年度利润分配预案或公积金转增股本预案。 六、 前瞻性陈述的风险声明 √适用 □不适用 公司已在本报告中描述了可能存在的相关风险，敬请投资者查阅本报告第三节"管理层讨论与分 析"中"可能面对的风险"部分。 十一、 其他 □适用 √不适用 半年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，投资者及相关人士均 应当对此保持足够 ...

Core Insights - The pharmaceutical commercial sector experienced a slight increase of 0.05% on August 22, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Group 1: Stock Performance - Saily Medical (603716) saw a closing price of 31.52, with a significant increase of 10.02% and a trading volume of 614,300 shares, resulting in a transaction value of 1.861 billion yuan [1] - Guofang Co. (600538) closed at 6.55, up 2.18%, with a trading volume of 218,500 shares [1] - Runda Medical (603108) closed at 18.35, up 1.94%, with a trading volume of 303,900 shares [1] - Other notable stocks include Jiuzhoutong (600998) with a slight increase of 0.55% and Yifeng Pharmacy (603939) with a minimal increase of 0.20% [1] Group 2: Capital Flow - The pharmaceutical commercial sector saw a net inflow of 363 million yuan from main funds, while retail investors experienced a net outflow of 114 million yuan [2] - Speculative funds recorded a net outflow of 249 million yuan [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of HeFu China, which has a high PE ratio compared to its industry peers [1][2] - HeFu China's closing price on August 19 was 7.25 yuan, reflecting a 2.55% increase, with a rolling PE ratio of 199.97 times and a total market capitalization of 2.886 billion yuan [1] - The average PE ratio for the pharmaceutical commercial industry is 42.14 times, with a median of 30.04 times, positioning HeFu China at 27th among its peers [1][2] Group 2 - As of the first quarter of 2025, two institutions hold shares in HeFu China, with a total of 560,000 shares valued at 0.04 million yuan [1] - HeFu China specializes in international trade and after-sales services related to in vitro diagnostic medical devices and consumables, as well as hospital information management system consulting services [1] - The latest financial results for the first quarter of 2025 show HeFu China achieved revenue of 176 million yuan, a year-on-year decrease of 26.35%, and a net profit of -6,001,192.11 yuan, a year-on-year decline of 184.13%, with a gross profit margin of 16.71% [1]

Core Viewpoint - The implementation of new policies in 2024 has led to a significant increase in cash dividends among listed companies in China's stock markets, with a total cash dividend amounting to approximately 2.4 trillion yuan, marking a historical high in both scale and frequency [1] Group 1: Dividend Trends - In 2024, a total of 3,755 listed companies in the Shanghai and Shenzhen stock markets implemented cash dividends, with the number of dividend-paying companies and the total amount increasing by 11.7% and 14.7% respectively compared to 2023 [1] - The trend of high dividends is particularly notable among the 498 listed biopharmaceutical companies, with 43 companies having a dividend payout ratio exceeding 90%, and 32 of those exceeding 100% [2] Group 2: Company-Specific Analysis - For example, HeFu China reported a revenue of 939 million yuan in 2024, a decline of 14.05% year-on-year, and a net profit of 27.57 million yuan, down 41.58% year-on-year, despite maintaining a high dividend payout [2] - HeFu China's cash dividend for 2024 reached 52 million yuan, with a dividend payout ratio of 187.72%, indicating a trend of distributing more than the net profit [2][3] Group 3: Risks of High Dividend Policies - The phenomenon of "clearance-style dividends," where companies distribute nearly all of their net profits, raises concerns about future sustainability and financial reserves, potentially undermining funds for reinvestment and growth [1][3] - High dividend payouts, especially when funded by initial public offering (IPO) proceeds, can distort the capital market's resource allocation function, benefiting major shareholders at the expense of long-term company health and smaller shareholders [3]

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.01% on August 13, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with the following notable movements: - Seli Medical (603716) rose by 6.55% to a closing price of 31.09, with a trading volume of 556,200 shares and a transaction value of 1.671 billion [1] - Guofa Co. (600538) increased by 1.75% to 6.38, with a trading volume of 129,600 shares [1] - Huaren Health (301408) fell by 1.76% to 15.11, with a trading volume of 179,600 shares and a transaction value of 271 million [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 33.73 million from institutional investors, while retail investors experienced a net outflow of 42.05 million [2] - Notable capital flows for specific stocks included: - Seli Medical had a net inflow of 10.9 million from institutional investors, while retail investors saw a net outflow of 2.46 million [3] - Yiyang Pharmaceutical (301015) had a net inflow of 6.29 million from institutional investors, but retail investors faced a net outflow of 31.02 million [3]

Business Performance - Luxshare Technology plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - China Shipbuilding Industry Corporation will suspend trading from August 13 until delisting [1] - Hikvision's chairman proposed a mid-term dividend of 4 yuan per 10 shares (including tax) for 2025 [1] - North Medical's subsidiary has essentially halted its main business since June [1] - Shenzhen Huangting Plaza will be judicially auctioned with a starting price of 3.053 billion yuan [1] - ST Suwu's controlling subsidiary has initiated arbitration against Regen Biotech for default, which has been accepted [1] - ST Yigou plans to pay 220 million yuan to reach a debt settlement agreement with Carrefour [1] - Shanghai Jianke's director is under disciplinary review and investigation [1] Mergers and Acquisitions - Xincheng Technology has terminated the acquisition of 96.96% equity in Tianyi Enhua [1] - Guangku Technology intends to purchase 100% equity in Suzhou Anjie Xun Optoelectronics, with resumption of trading on the 12th [1] - ST Biology plans to acquire 51% equity in Huize Pharmaceutical, expected to constitute a major asset restructuring [1] - Dongfang Guoxin aims to gain control of Shituo Cloud to deepen its layout in the intelligent computing power sector [1] - Jinding Investment intends to control Nanjing Shenyuan, entering a key segment of the robotics industry chain [1] - Huangshanghuang plans to acquire 51% equity in Lixing Food for 495 million yuan [1] Financial Performance - Xianggang Technology reported a net profit of 78.32 million yuan in the first half, a year-on-year increase of 432.14% [1] - Yonghe Co. reported a net profit of 271 million yuan in the first half, a year-on-year increase of 140.82% [1] - Fuda Co. reported a net profit of 146 million yuan in the first half, a year-on-year increase of 98.77% [1] - Desay SV reported a net profit of 1.223 billion yuan in the first half, a year-on-year increase of 45.82% [1] - Dier Laser reported a net profit of 327 million yuan in the first half, a year-on-year increase of 38.37% [1] - Rijiu Optoelectronics reported a net profit of 45.61 million yuan in the first half, a year-on-year increase of 37.87% [1] - Wolong Electric Drive reported a net profit of 537 million yuan in the first half, a year-on-year increase of 36.76% [1] - Satellite Chemical reported a net profit of 2.744 billion yuan in the first half, a year-on-year increase of 33.44% [1] Other Financial Results - High Stakes Mining reported a net profit of 69.2 million yuan in the first half, a year-on-year increase of 25.7% [2] - Yingliu Co. reported a net profit of 188 million yuan in the first half, a year-on-year increase of 23.91% [2] - Nanwei Medical reported a year-on-year net profit increase of 17.04% and plans to distribute a dividend of 5 yuan per 10 shares (including tax) [2] - Zhejiang Huaye reported a year-on-year net profit increase of 6.66% and plans to distribute a dividend of 4 yuan per 10 shares (including tax) [2] - New Strong Union reported a net profit of 400 million yuan in the first half, returning to profitability [2] - Aobi Zhongguang reported a net profit of 60.19 million yuan in the first half, returning to profitability [2] - Action Education reported a year-on-year net profit decrease of 3.51% and plans to distribute a dividend of 10 yuan per 10 shares (including tax) [2] - Wanhu Chemical reported a net profit of 6.123 billion yuan in the first half, a year-on-year decrease of 25.10% [2] - New World reported a net profit of 78.03 million yuan in the first half, a year-on-year decrease of 30.01% [2] - Huafeng Chemical reported a net profit of 983 million yuan in the first half, a year-on-year decrease of 35.23% [2] - Hefo China reported a consolidated revenue of 425 million yuan in the first seven months, a year-on-year decrease of 22.66%, with a narrowing decline [2] - Shengnong Development reported a sales revenue of 2.129 billion yuan in July, a year-on-year increase of 22.02% [2] - Xiamen Airport reported a passenger throughput of 2.6248 million in July, a year-on-year increase of 8.58% [2]

Core Viewpoint - The company reported a decline in consolidated revenue for the first seven months of 2025, indicating a continued but improving trend in revenue performance compared to the previous year [1] Group 1: Revenue Performance - The consolidated revenue for the period from January to July 2025 was RMB 425.1274 million, representing a decrease of 22.66% compared to the same period last year [1] - For the first six months of 2025, the consolidated revenue also showed a decline of 23.53% year-on-year, although the rate of decline has narrowed by 0.87% [1]